| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 2617.1 | 2269.9 | 2043.7 |
| Other income | 35.9 | 89.4 | 65.6 |
| Total income | 2653.0 | 2359.3 | 2109.3 |
| Profit before exceptional items & tax | 81.6 | -7.5 | -46.2 |
| Profit before tax | 81.6 | -7.5 | -46.2 |
| Net profit | 5.0 | -69.4 | -99.2 |
| Operating margin | 3.1% | -0.3% | -2.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +28.10% |
|---|---|
| Operating profit, year on year | +140.90% |
| Operating profit, quarter on quarter | +147.20% |
BSE results filing, NSE: PPLPHARMA. Figures extracted from the filing.
Piramal Pharma Ltd: key numbers
- Share price
- ₹230.60
- Market cap
- ₹30,701 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -147.0×Sector 46.5×
- Promoter holding
- 34.80%+0.00% QoQ
- FII holding
- 13.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Piramal Pharma Ltd
All →Piramal Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹2,617 Cr (+28% YoY), EBITDA margin 14.7% (+372 bps), PAT ₹5 Cr vs loss of ₹99 Cr. FY27 revenue growth outlook raised to 19-20%.
Piramal Pharma Results Update
Piramal Pharma released its Q2/H1 FY27 press release reporting revenue of Rs. 2,617 crore for Q2 and Rs. 4,887 crore for H1, with EBITDA up 72%. The filing also upgrades FY27 revenue growth guidance to 19–20%.
Piramal Pharma Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026. The report details equity distribution among promoters and public shareholders.
Piramal Pharma Board Meeting Date
Piramal Pharma Limited has scheduled a board meeting on October 27, 2026. The board will consider and approve unaudited financial results for the quarter ended September 30, 2026.
Piramal Pharma Adverse Business Impact
Piramal Pharma announced that its sales and distribution arrangement with Bayer Pharmaceuticals will expire on December 31, 2026, and will not be renewed.
- From
- Bayer Pharmaceuticals Private Limited
Piramal Pharma Price Movement Clarification
Piramal Pharma clarified a news item regarding a $1.7 million (₹11.39 Cr) investment from the Government of Ontario, stating it does not require material disclosure.
- Value
- ₹11.39 Cr